{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:52:27Z","timestamp":1779918747871,"version":"3.53.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.hoc.2022.03.012","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T07:29:46Z","timestamp":1656314986000},"page":"865-878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ex\u00a0Vivo and In\u00a0Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art"],"prefix":"10.1016","volume":"36","author":[{"given":"Giulia","family":"Consiglieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ester","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Brunetti-Pierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2022.03.012_bib2","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3421","article-title":"The mucopolysaccaridoses","author":"Neufeld","year":"2001"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.012_bib3","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.012_bib4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/14712598.2021.1895746","article-title":"Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses","volume":"21","author":"Safary","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.hoc.2022.03.012_bib5","doi-asserted-by":"crossref","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","article-title":"Therapy for the mucopolysaccharidoses","volume":"50","author":"Valayannopoulos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.hoc.2022.03.012_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jcpt.12136","article-title":"Current and potential therapeutic strategies for mucopolysaccharidoses","volume":"39","author":"Noh","year":"2014","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.012_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A\u00a0phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.012_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A\u00a0phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2022.03.012_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgme.2015.07.005","article-title":"Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I","volume":"116","author":"Dickson","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.hoc.2022.03.012_bib10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2022.03.012_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","article-title":"The clinical outcome of hurler syndrome after stem cell transplantation","volume":"14","author":"Aldenhoven","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.hoc.2022.03.012_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10545-015-9900-2","article-title":"Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?","volume":"39","author":"Tomatsu","year":"2016","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.012_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.012_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.012_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in\u00a0vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"issue":"18","key":"10.1016\/j.hoc.2022.03.012_bib16","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2022.03.012_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coviro.2016.08.006","article-title":"Crossing the blood-brain-barrier with viral vectors","volume":"21","author":"Fu","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.hoc.2022.03.012_bib18","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.hoc.2022.03.012_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"issue":"10322","key":"10.1016\/j.hoc.2022.03.012_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2022.03.012_bib21","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2022.03.012_bib22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/hum.2016.068","article-title":"Preclinical testing of the safety and tolerability of lentiviral vector\u2013mediated above-normal alpha-l-iduronidase expression in murine and human hematopoietic cells using toxicology and biodistribution good laboratory practice studies","volume":"27","author":"Visigalli","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"37","key":"10.1016\/j.hoc.2022.03.012_bib23","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"21","key":"10.1016\/j.hoc.2022.03.012_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.012_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nbd.2011.02.015","article-title":"Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I","volume":"43","author":"Wolf","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"12","key":"10.1016\/j.hoc.2022.03.012_bib26","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol Ther"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2022.03.012_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2016.06.006","article-title":"Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model","volume":"119","author":"Hinderer","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.hoc.2022.03.012_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"15","key":"10.1016\/j.hoc.2022.03.012_bib29","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In\u00a0vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.012_bib30","first-page":"S104","article-title":"CHAMPIONS: A Phase 1\/2 clinical trial with dose escalation of SB-913 ZFN-mediated in\u00a0vivo human genome editing for treatment of MPSII (Hunter syndrome)","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.hoc.2022.03.012_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nbt0118-5b","article-title":"First in\u00a0vivo human genome editing trial","volume":"36","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.012_bib32","first-page":"e8730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"Mol Med"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.012_bib33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of neurocognitive deficiency in mucopolysaccharidosis type II mice by central nervous system-directed, AAV9-mediated iduronate sulfatase gene transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.012_bib34","doi-asserted-by":"crossref","first-page":"e86696","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.hoc.2022.03.012_bib35","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/hum.2016.101","article-title":"Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice","volume":"27","author":"Hinderer","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"4S1","key":"10.1016\/j.hoc.2022.03.012_bib36","first-page":"231","article-title":"Preliminary outcomes of haematopoietic stem cell gene therapy in a patient with mucopolysaccharidosis IIIA","volume":"28","author":"Kinsella","year":"2020","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.012_bib37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/j.hoc.2022.03.012_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.hoc.2022.03.012_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.012_bib40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0092-8674(03)00348-9","article-title":"The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases","volume":"113","author":"Cosma","year":"2003","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2022.03.012_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(03)00347-7","article-title":"Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme","volume":"113","author":"Dierks","year":"2003","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.hoc.2022.03.012_bib42","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/hmg\/ddm223","article-title":"Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes","volume":"16","author":"Fraldi","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.012_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/hum.2015.170","article-title":"A\u00a0Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome","volume":"27","author":"Winner","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.012_bib44","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1172\/JCI66778","article-title":"Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy","volume":"123","author":"Haurigot","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.012_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/mt.2011.220","article-title":"Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice","volume":"20","author":"Ruzo","year":"2012","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.hoc.2022.03.012_bib46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201202083","article-title":"A\u00a0highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA","volume":"5","author":"Sorrentino","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.hoc.2022.03.012_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2020.05.015","article-title":"Liver-targeted AAV8 gene therapy ameliorates skeletal and cardiovascular pathology in a mucopolysaccharidosis IVA murine model","volume":"18","author":"Sawamoto","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.hoc.2022.03.012_bib48","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1038\/s41467-021-25697-y","article-title":"Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy","volume":"12","author":"Bertolin","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.012_bib49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/mt.2010.257","article-title":"Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer","volume":"19","author":"Cotugno","year":"2011","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.012_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/hum.2012.179","article-title":"Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8","volume":"24","author":"Ferla","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.012_bib51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2013.213","article-title":"Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease","volume":"25","author":"Ferla","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hoc.2022.03.012_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.omtm.2017.07.004","article-title":"Non-clinical Safety and Efficacy of an AAV2\/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI","volume":"6","author":"Ferla","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.hoc.2022.03.012_bib53","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/brain\/awy126","article-title":"A\u00a0novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency","volume":"141","author":"Tordo","year":"2018","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.hoc.2022.03.012_bib54","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/hmg\/ddx058","article-title":"Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID","volume":"26","author":"Roca","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"13","key":"10.1016\/j.hoc.2022.03.012_bib55","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2022.03.012_bib56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10545-010-9262-8","article-title":"Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H)","volume":"34","author":"Gardner","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.hoc.2022.03.012_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1750-1172-8-155","article-title":"Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure","volume":"8","author":"Langereis","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.hoc.2022.03.012_bib58","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2017.5","article-title":"Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome","volume":"52","author":"Lum","year":"2017","journal-title":"Bone Marrow Transpl"},{"issue":"19","key":"10.1016\/j.hoc.2022.03.012_bib59","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.012_bib60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hoc.2022.03.012_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122S","author":"Scarpa","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.hoc.2022.03.012_bib62","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin Perinatol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:18:22Z","timestamp":1760185102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889858822000338"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.012","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex\u00a0Vivo and In\u00a0Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}